Alentis Therapeutics: Valuation, Funding & Investors
Alentis Therapeutics is a clinical-stage biotechnology company based in Basel, Switzerland, focused on developing a pipeline of Claudin-1 (CLDN1) targeted medicines. The company aims to create first-in-class therapies that address unmet medical needs by targeting CLDN1, a key player in various pathological processes.
Leadership & Board
Key Executives
- CEO
- Andrea Pellacani
- CEO
- Roberto Iacone
- Chief Executive Officer
- Mark Pruzanski
- Chief Business Officer
- Rizwan Velji
- Current Number of Employees
- 73
- Current LinkedIn Followers
- 17,246
Latest Estimated Valuation
- Total Amount Raised
- $181M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $181M
- Latest Funding Round
- Series D
Employee Trend
Alentis Therapeutics had 73 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
73Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Alentis Therapeutics had 17,246 followers as of November 16, 2026. The number of followers increased by 163 (0.95%) week-over-week.
17,246Latest Followers Count
163(0.95%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series D | $181.40M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Novo Holdings | Series D |
Similar Companies
A snapshot of private companies similar to Alentis Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis









